Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis - a primary driver of cardiovascular death worldwide - in large mammals, a study suggests.

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

With colleagues in Graz and Copenhagen, the lipid metabolism expert has studied how treatment of LAL deficiency with lanifibranor works. Reduces liver damage and improves blood lipid levels ...

Maternal BMI had no impact on IHCL in VD infants (p=0.81). Conclusion: VD may activate pathways that protect against liver lipid accumulation in the presence of increasing maternal BMI.